(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 June 2010 (17.06.2010)

PCT

(10) International Publication Number
WO 2010/067900 A1

(51) International Patent Classification:
G01N 33/49 (2006.01) *G01N 33/15* (2006.01)
A61K 31/551 (2006.01) *G01N 33/50* (2006.01)

(21) International Application Number:
PCT/JP2009/071070

(22) International Filing Date:
11 December 2009 (11.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0801006378 12 December 2008 (12.12.2008) TH

(71) Applicants *(for all designated States except US)*: **Mahidol University** [TH/TH]; 999 Phuttamonthon 4 Road, Salaya, Nakhon Pathom, 73170 (TH). **Thailand Center of Excellence for Life Sciences(OKMD)** [TH/TH]; 22nd Fl., CMMU Building, 69 Vibhavadi-Rangsit Road, Samsen Nai, Phayathai, Bangkok, 10400 (TH). **Department of Medical Sciences, Ministry of Public Health** [TH/TH]; 88/7 Soi Bamrasnaradura, Tivanond Rd., Nonthaburi, 11000 (TH). **RIKEN** [JP/JP]; 2-1, Hirosawa, Wako-shi, Saitama, 3510198 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SUNGKANUPARPH, Somnuek. KIERTIBURANAKUL, Sasisopin. SURA, Thanyachai. CHANTRATITA, Wasun. CHANTARANGSU, Soranun. CHAROENYINGWATTANA, Angkana. MAHASIRIMONGKOL, Surakameth. KUBO, Michiaki. MUSHIRODA, Taisei. NAKAMURA, Yusuke.**

(74) Agent: **HARAKENZO WORLD PATENT & TRADEMARK**; Daiwa Minamimorimachi Building, 2-6, Tenjinbashi 2-chome Kita, Kita-ku, Osaka-shi, Osaka, 5300041 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/067900 A1

(54) Title: RISK ASSESSMENT FOR CUTANEOUS ADVERSE DRUG REACTIONS FROM ANTIRETROVIRAL AGENT

(57) Abstract: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.